Clinical Trials

Title   Phase IV Study: CLCZ696BUS13: A 52 week, open label evaluation of the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction (PR
Description   This study is to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapyover a period of 12 months, and correlate these biomarker changes with cardiac remodeling parameters, patient-reported outcomes and cardiovascular outcomes.
IRB Number   1061296-2
Treatment   Cardiovascular
Status   Active
Principal Name   Christopher Malozzi, DO
Contact Name   Cherie Revere

Email Newsletters

Connect With Us